We are live on
!
Find out more
FFM
Fairmount Funds Management Portfolio holdings
AUM
$1.38B
1-Year Est. Return
407.79%
This Fund
S&P 500
This Quarter
Est. Return
+73.9%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$1.31B
AUM Growth
+$202M
(+18%)
Cap. Flow
-$257M
Cap. Flow
% of AUM
-19.57%
Top 10 Holdings %
Top 10 Hldgs %
92.03%
Holding
17
New
–
Increased
5
Reduced
2
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CBIO
Crescent Biopharma
CBIO
|
+$17.3M |
| 2 |
JBIO
Jade Biosciences
JBIO
|
+$15.6M |
| 3 |
Viridian Therapeutics
VRDN
|
+$12.5M |
| 4 |
ZBIO
Zenas BioPharma
ZBIO
|
+$10.4M |
| 5 |
Inhibikase Therapeutics
IKT
|
+$3.98M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axsome Therapeutics
AXSM
|
+$99M |
| 2 |
Scholar Rock
SRRK
|
+$67.9M |
| 3 |
ABVX
Abivax
ABVX
|
+$60.6M |
| 4 |
Dianthus Therapeutics
DNTH
|
+$45.4M |
| 5 |
ATXS
Astria Therapeutics
ATXS
|
+$25.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cogent Biosciences
COGT
$6.68B
| $320M | 24.34% |
9,003,418
| – | – |
|
2
Apogee Therapeutics
APGE
$10.1B
| $155M | 11.77% |
2,048,647
| – | – |
|
3
Spyre Therapeutics
SYRE
$8.7B
| $132M | 10.02% |
4,018,101
| – | – |
|
|
4
Viridian Therapeutics
VRDN
$1.99B
| $122M | 9.27% |
3,914,458
+454,545
| +13% | +$12.5M |
|
|
ORKA
5
Oruka Therapeutics
ORKA
$5.59B
| $112M | 8.55% |
3,705,262
| – | – |
|
|
6
Dianthus Therapeutics
DNTH
$5.77B
| $88.1M | 6.7% |
2,137,191
-1,170,000
| -35% | -$45.4M |
|
|
ZBIO
7
Zenas BioPharma
ZBIO
$1.86B
| $80.2M | 6.11% |
2,209,025
+316,219
| +17% | +$10.4M |
|
|
NUVL
8
DELISTED
Nuvalent
NUVL
| $73.2M | 5.57% |
727,563
| – | – |
|
|
JBIO
9
Jade Biosciences
JBIO
$1.27B
| $70.3M | 5.35% |
4,553,494
+1,333,126
| +41% | +$15.6M |
|
10
Enliven Therapeutics
ELVN
$3.8B
| $57.2M | 4.35% |
3,711,444
| – | – |
|
11
Kiniksa Pharmaceuticals
KNSA
$4.92B
| $54.4M | 4.14% |
1,319,688
-453,151
| -26% | -$18.2M |
|
|
CBIO
12
Crescent Biopharma
CBIO
$407M
| $32.6M | 2.48% |
2,747,866
+1,360,000
| +98% | +$17.3M |
|
|
13
Inhibikase Therapeutics
IKT
$331M
| $17.7M | 1.35% |
8,625,000
+2,500,000
| +41% | +$3.98M |
|
|
ABVX
14
Abivax
ABVX
$11.9B
| – | – |
-713,434
| Closed | -$60.6M |
|
|
ATXS
15
DELISTED
Astria Therapeutics
ATXS
| – | – |
-3,554,129
| Closed | -$25.9M |
|
|
16
Axsome Therapeutics
AXSM
$11.8B
| – | – |
-815,176
| Closed | -$99M |
|
|
17
Scholar Rock
SRRK
$6.33B
| – | – |
-1,824,031
| Closed | -$67.9M |
|
Similar funds
NIP
OCAM
AU
RIM
VC
AO
1CP
OCM
Fairmount Funds Management's Q4 2025 Portfolio in Review
As of Q4 2025, Fairmount Funds Management held 17 positions worth $1.31B, up 18% from $1.11B the previous quarter. Its ten largest holdings account for 92% of the portfolio.
Fairmount Funds Management withdrew a net $257M in Q4 2025, closing 4 positions and reducing 2 holdings. Its most notable exit was Axsome Therapeutics, an estimated $99M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Fairmount Funds Management added an estimated $17.3M to Crescent Biopharma.
- Fairmount Funds Management added most to Crescent Biopharma in Q4 2025, an estimated $17.3M increase.
- Fairmount Funds Management's biggest Q4 2025 reduction was Dianthus Therapeutics, cutting an estimated $45.4M.
- Fairmount Funds Management fully exited Axsome Therapeutics in Q4 2025, selling an estimated $99M.
- Fairmount Funds Management's ten largest holdings make up 92% of its $1.31B portfolio in Q4 2025.
- Fairmount Funds Management opened 0 new positions and closed 4 in Q4 2025.
- Fairmount Funds Management's portfolio value rose 18% quarter-over-quarter to $1.31B.
Based on Fairmount Funds Management's 13F filing for Q4 2025, filed 17 Feb 2026.